Sanofi is reported to be preparing a move to take control of US biotech Ocular Therapeutix, after an initial bid was rejected last year. That is according to French newspaper La Lettre, which said ...
Bristol Myers Squibb has ended the week with an agreement to buy Orbital Therapeutics – a developer of in vivo cell therapies – for $1.5 billion in cash. Cambridge, Massachusetts-based Orbital is ...
Ocular Therapeutix (OCUL) is a Strong Buy, driven by the pivotal SOL-1 Phase 3 trial for AXPAXLI™ in wet AMD, with topline results expected Q1 2026. AXPAXLI™ leverages proven science and a de-risked ...
BEDFORD, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today ...
SOL-1 Phase 3 superiority trial results remain masked to date SOL-1 data expected to be presented at the 49 th Macula Society Annual Meeting Ocular plans to submit NDA for AXPAXLI™ in wet AMD based on ...
Earnings call OpenText delivered Q2 FY26 revenue of $1.33B, exceeding internal expectations, with 3.4% YoY cloud revenue growth and 18% growth in enterprise cloud bookings. Management reaffirmed FY26 ...
In this episode of New Zealand Channel Voices, Reseller News speaks with Rana Stephan, winner of the 2024 Women in ICT Achievement Award, about her 30-year journey in the technology sector and the key ...
Zach Bryan has entered the 2026 Super Bowl halftime battle chat, slamming Turning Point USA for putting on a rival show during Bad Bunny's official performance. "I don't care what side you're on, a ...
Unmask the hidden before the world does. An AI-powered agentic red team framework that automates offensive security operations, from reconnaissance to exploitation to post-exploitation, with zero ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results